Supporting this notion, targeting the PI3K-AKT-mTOR pathway has been shown to modulate the immunosuppressive microenvironment, enhancing the sensitivity to tumor-specific CD8+ T-cell-mediated cytotoxicity, and augmenting the effect of immunotherapy [44,45]. The gene discussed is AKT1; the disease is neoplasm.